News

reMYND signs license agreement
20-12-2007

reMYND signs a license agreement with another biotech company for their internal use of reMYND’s proprietary APPLon model.

reMYND's Parkinson's disease drug discovery program reaches breakthrough
26-03-2007

reMYND nv announced today that it has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease.